LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

LLY

1,000.43

-2.27%↓

JNJ

245.85

-0.77%↓

ABBV

232.91

+0.01%↑

NVS

162.5

-2.75%↓

MRK

120.48

-0.53%↓

Home・Elenco Azioni・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Aperta

7.08 6.63

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.5600000000000005

Massimo

7.15

Metriche Chiave
By Trading Economics
P/E Media del settore	2.462 108.767
EPS	-0.36
Dipendenti	8

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-39.39% downside

Dividendi
By Dow Jones
Utili prossimi	9 mar 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	215M 239M
Apertura precedente	0.45
Chiusura precedente	7.08

Minerva Neurosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ott 2025, 15:58 UTC

I principali Market Mover

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Confronto tra pari

Modifica del prezzo

Minerva Neurosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

-39.39% in calo

Previsioni per 12 mesi

Media 4 USD -39.39%

Alto 4 USD

Basso 4 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Minerva Neurosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Minerva Neurosciences Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Chi Siamo Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.